Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dong-A Ties With NeuroBo For Diabetic Neuropathy, Alzheimer's

Executive Summary

Dong-A makes notable progress in botanical drug programs, reaching deals for its diabetic neuropathic pain and Alzheimer's disease drug assets with Boston-based NeuroBo Pharmaceuticals.

Advertisement

Related Content

Biotech Deals Stand Out In 2018 Korean Licensing Trends
Oncology, Diabetes Dominate Korean Out-Licensing But Deals And Value Decline
Eased Tensions On Korean Peninsula To Fuel Botanical Drug R&D?
Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine
Momentum For ViroMed's Gene Therapy After ‘Exceptional’ Trial Go-Ahead In China
Dong-A Progresses In Diabetes With Lat Am Deal, New Study

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100229

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel